COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk / World Health Organization (WHO) (REPI)
SARS-COV-2 (virus Responsible of COVID-19) Reinfection and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk: Matched Case-control Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
This study is based to data collection of cases (patients with MIS-C) compare to controls (patients with SARS-CoV-2 infection) occurring between 01 sep 2021 and 30 apr 2022. For this study cases and controls group will be matched for analyses.
The main of this study is to evaluate the difference of risk of occurrence of MIS-C between a first SARS-CoV-2 infection and a reinfection with SARS-CoV-2.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Corinne Levy, physician
- Phone Number: +33 1 48 85 04 04
- Email: corinne.levy@activ-france.fr
Study Contact Backup
- Name: Stéphane Béchet, Data Manager
- Phone Number: +33 1 48 85 96 38
- Email: stephane.bechet@activ-france.fr
Study Locations
-
-
-
Créteil, France, 94000
- ACTIV
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
group 1: cases
- Patients with MIS-C (following SARS CoV-2 infection)
- Hospitalised between the 01 sep 2021 and 30 apr 2022
- Under 18 years of age
- Not vaccinated for SARS-CoV-2
group 2: controls
- Patients not hospitalised, treated by outpatient care
- With documented SARS-CoV-2 infection between the 01 sep 2021 and 30 apr 2022
- Matched with a case on age (+/- 6 months), gender and country
- Not vaccinated for SARS-CoV-2
Exclusion Criteria:
- Refusal to participate by patient relative or legal representative
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
children with MIS-C
hospitalized children with MIS-C
|
|
SARS-CoV-2 infection
non hospitalized children infected with SARS-CoV-2 treated by outpatient care
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
proportion of MIS-C cases occurred after first SARS-CoV-2 infection
Time Frame: 8 months
|
Assessment of risk of MIS-C after first SARS-CoV-2 infection
|
8 months
|
|
proportion of MIS-C cases occurred after SARS-CoV-2 reinfection
Time Frame: 8 months
|
Assessment of risk of MIS-C after SARS-CoV-2 reinfection
|
8 months
|
|
Proportion of SARS-CoV-2 reinfection after first SARS-CoV-2 infection
Time Frame: 8 months
|
Assessment of risk of SARS-CoV-2 reinfection after first SARS-CoV-2 infection
|
8 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Corinne Levy, Physician, Association Clinique Thérapeutique Infantile du val de Marne
- Principal Investigator: Naim Ouldali, Physician, Hôpital Robert Debré AP-HP, Paris 19
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- REPI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.